RLS Radiopharmacies

RLS Radiopharmacies was the leading national radiopharmacy network in the US, delivering PET, SPECT, and therapeutic radiopharmaceuticals through 31 facilities in 18 states and serving over 1,500 customers. The company held Joint Commission accreditation and supplied high-quality, state-of-the-art molecular imaging products, leveraging proprietary clean rooms and advanced production and distribution technology. RLS was acquired by Telix Pharmaceuticals in September 2024, immediately expanding Telix’s US manufacturing and last-mile distribution for radiopharmaceuticals including FDA-approved agents like gallium-68 gozetide (Illuccix) for prostate cancer imaging[5][9][8][3][1].